EQS-News
aap successfully places a 10% capital increase from authorized capital at EUR 1.10 with exclusion of subscription rights
- aap Implantate AG successfully places 10% capital increase at EUR 1.10, excluding subscription rights.
- Premium to current share price of EUR 0.8 is 37.5%, raising EUR 986,311.70 in liquid funds.
- Cash inflow will strengthen resources for ongoing human clinical trial of antibacterial implant technology.
EQS-News: aap Implantate AG / Key word(s): Capital Increase
|
aap Implantate AG ("aap" or "Company") successfully completed the 10% capital increase announced on March 18, 2024 with exclusion of subscription rights at a placement price of EUR
1.10, which corresponds to a premium of 37.5%. The company will thus receive liquid funds of EUR 986,311.70. This cash inflow will strengthen the company's own resources for the ongoing human
clinical trial of the innovative antibacterial implant technology. The investors have also already signaled that they will provide further funds if business develops positively.
----------------------------------------------------------------
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock exchanges -
About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, produces and markets products for traumatology. In addition to the innovative LOQTEQ anatomical plate system, the IP-protected portfolio includes a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while internationally it primarily uses a broad network of distributors in around 25 countries. In the United States, the company relies on a sales strategy via distribution agents through its subsidiary aap Implants Inc. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.